Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Parasitol ; 204: 107728, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31348915

ABSTRACT

BACKGROUND: Co-infection with Leishmania major and Schistosoma mansoni may have significant consequences for disease progression, severity and subsequent transmission dynamics. Pentavalent antimonials and Praziquantel (PZQ) are used as first line of treatment for Leishmania and Schistosoma infections respectively. However, there is limited insight on how combined therapy with the standard drugs impacts the host in comorbidity. The study aimed to determine the efficacy of combined chemotherapy using Pentostam (P) and PZQ in murine model co-infected with L. major and S. mansoni. METHODS: A 3 × 4 factorial design with three parasite infection groups (Lm, Sm, Lm + Sm to represent L. major, S. mansoni and L. major + S. mansoni respectively) and four treatment regimens [P, PZQ, P + PZQ, and PBS designating Pentostam (GlaxoSmithKline UK), Praziquantel (Biltricide®, Bayer Ag. Leverkusen, Germany), Pentostam + Praziquantel and Phosphate buffered saline] as factors was applied. RESULTS: Significant changes were observed in the serum Interferon gamma (IFN-γ), and Macrophage inflammatory protein-one alpha (MIP-1α) levels among various treatment groups between week 8 and week 10 (p < 0.05). There was increased IFN-γ in the L. major infected mice subjected to PZQ and PBS, and in L. major + S. mansoni infected BALB/c mice treated with P + PZQ. Subsequently, MIP-1α levels increased significantly in both the L. major infected mice under PZQ and PBS and in L. major + S. mansoni infected BALB/c mice undergoing concurrent chemotherapy with P + PZQ between 8 and 10 weeks (p < 0.05). In the comorbidity, simultaneous chemotherapy resulted in less severe histopathological effects in the liver. CONCLUSION: It was evident, combined first line of treatment is a more effective strategy in managing co-infection of L. major and S. mansoni. The findings denote simultaneous chemotherapy compliments immunomodulation in the helminth-protozoa comorbidity hence, less severe pathological effects following the parasites infection. Recent cases of increased incidences of polyparasitism in vertebrates call for better ways to manage co-infections. The findings presented necessitate intrinsic biological interest on examining optimal combined chemotherapeutic agents strategies in helminth-protozoa concomitance and the related infections abatement trends vis-a-vis host-parasite relationships.


Subject(s)
Anthelmintics/therapeutic use , Antiprotozoal Agents/therapeutic use , Comorbidity , Leishmania major/pathogenicity , Leishmaniasis, Cutaneous/complications , Schistosomiasis mansoni/complications , Analysis of Variance , Animals , Anthelmintics/administration & dosage , Antimony Sodium Gluconate/administration & dosage , Antimony Sodium Gluconate/therapeutic use , Antiprotozoal Agents/administration & dosage , Chemokine CCL3/blood , Disease Models, Animal , Drug Therapy, Combination , Interferon-gamma/blood , Leishmania major/drug effects , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/pathology , Liver/parasitology , Liver/pathology , Mice , Mice, Inbred BALB C , Praziquantel/administration & dosage , Praziquantel/therapeutic use , Schistosoma mansoni/drug effects , Schistosoma mansoni/pathogenicity , Schistosomiasis mansoni/drug therapy , Schistosomiasis mansoni/immunology , Schistosomiasis mansoni/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...